{"id":"carafate","rwe":[],"_fda":{"id":"cb835be9-f4ba-47c4-b1db-d2f731371432","set_id":"0fb67b1c-b4c0-46f2-8a81-df1510e006aa","openfda":{"nui":["N0000175801","M0015420"],"unii":["XX73205DH5"],"route":["ORAL"],"rxcui":["208094","313123"],"spl_id":["cb835be9-f4ba-47c4-b1db-d2f731371432"],"brand_name":["Carafate"],"spl_set_id":["0fb67b1c-b4c0-46f2-8a81-df1510e006aa"],"package_ndc":["58914-170-14","58914-170-60"],"product_ndc":["58914-170"],"generic_name":["SUCRALFATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Organometallic Compounds [CS]"],"substance_name":["SUCRALFATE"],"pharm_class_epc":["Aluminum Complex [EPC]"],"manufacturer_name":["Allergan, Inc."],"application_number":["NDA019183"],"is_original_packager":[true]},"version":"20","warnings":["WARNINGS Fatal complications, including pulmonary and cerebral emboli have occurred with inappropriate intravenous administration of CARAFATE Oral Suspension. Administer CARAFATE Oral Suspension only by the oral route. Do not administer intravenously."],"pregnancy":["Pregna n c y Teratogenic effects Teratogenicity studies have been performed in mice, rats, and rabbits at doses up to 50 times the human dose and have revealed no evidence of harm to the fetus due to sucralfate. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed."],"overdosage":["OVERDOSAGE Due to limited experience in humans with overdosage of sucralfate, no specific treatment recommendations can be given. Acute oral studies in animals, however, using doses up to 12 g/kg body weight, could not find a lethal dose. Sucralfate is only minimally absorbed from the gastrointestinal tract. Risks associated with acute overdosage should, therefore, be minimal. In rare reports describing sucralfate overdose, most patients remained asymptomatic. Those few reports where adverse events were described included symptoms of dyspepsia, abdominal pain, nausea, and vomiting."],"description":["DESCRIPTION CARAFATE Oral Suspension contains sucralfate and sucralfate is an α-D-glucopyranoside, β-D- fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. CARAFATE Oral Suspension for oral administration contains 1 g of sucralfate per 10 mL. CARAFATE Oral Suspension also contains: colloidal silicon dioxide NF, FD&C Red #40, flavor, glycerin USP, methylcellulose USP, methylparaben NF, microcrystalline cellulose NF, purified water USP, simethicone emulsion USP, and sorbitol solution USP. Therapeutic category: antiulcer. CARAFATE Oral Suspension contains sucralfate and sucralfate is an α-D-glucopyranoside, β-D- fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex."],"precautions":["PRECAUTIONS The physician should read the “ PRECAUTIONS ” section when considering the use of CARAFATE Oral Suspension in pregnant or pediatric patients, or patients of childbearing potential. Duodenal ulcer is a chronic, recurrent disease. While short-term treatment with sucralfate can result in complete healing of the ulcer, a successful course of treatment with sucralfate should not be expected to alter the post healing frequency or severity of duodenal ulceration. Episodes of hyperglycemia have been reported in diabetic patients. Close monitoring of glycemia in diabetic patients treated with CARAFATE Oral Suspension is recommended. Adjustment of the anti-diabetic treatment dose during the use of CARAFATE Oral Suspension might be necessary. Special Population s : C h ronic Re n al Failure and Dial y sis Patients When sucralfate is administered orally, small amounts of aluminum are absorbed from the gastrointestinal tract. Concomitant use of sucralfate with other products that contain aluminum, such as aluminum-containing antacids, may increase the total body burden of aluminum. Patients with normal renal function receiving the recommended doses of sucralfate and aluminum- containing products adequately excrete aluminum in the urine. Patients with chronic renal failure or those receiving dialysis have impaired excretion of absorbed aluminum. In addition, aluminum does not cross dialysis membranes because it is bound to albumin and transferrin plasma proteins. Aluminum accumulation and toxicity (aluminum osteodystrophy, osteomalacia, encephalopathy) have been described in patients with renal impairment. Sucralfate should be used with caution in patients with chronic renal failure. Drug Intera c tions Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. Subtherapeutic prothrombin times with concomitant warfarin and sucralfate therapy have been reported in spontaneous and published case reports. However, two clinical studies have demonstrated no change in either serum warfarin concentration or prothrombin time with the addition of sucralfate to chronic warfarin therapy. The mechanism of these interactions appears to be nonsystemic in nature, presumably resulting from sucralfate binding to the concomitant agent in the gastrointestinal tract. In all cases studied to date (cimetidine, ciprofloxacin, digoxin, norfloxacin, ofloxacin, and ranitidine), dosing the concomitant medication 2 hours before sucralfate eliminated the interaction. Due to CARAFATE Oral Suspension’s potential to alter the absorption of some drugs, CARAFATE Oral Suspension should be administered separately from other drugs when alterations in bioavailability are felt to be critical. In these cases, patients should be monitored appropriately. Carci n oge ne sis, Mutag en esis, Impairment of F e rt i li t y Chronic oral toxicity studies of 24 months’ duration were conducted in mice and rats at doses up to 1 g/kg (12 times the human dose). There was no evidence of drug-related tumorigenicity. A reproduction study in rats at doses up to 38 times the human dose did not reveal any indication of fertility impairment. Mutagenicity studies were not conducted. Pregna n c y Teratogenic effects Teratogenicity studies have been performed in mice, rats, and rabbits at doses up to 50 times the human dose and have revealed no evidence of harm to the fetus due to sucralfate. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when sucralfate is administered to a nursing woman. Pediatric U s e Safety and effectiveness in pediatric patients have not been established. Geriatric Use Clinical studies of CARAFATE Oral Suspension did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (See DOSAGE AND ADMINISTRATION ). This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function (See PRECAUTIONS Special Populations: Chronic Renal Failure and Dialysis Patients ). Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function."],"how_supplied":["HOW SUPPLIED CARAFATE (sucralfate) Oral Suspension 1 g/10 mL is a pink suspension supplied in bottles of 420 mL (NDC 58914-170-14). SHAKE WELL BEFORE USIN G . AVOID FREEZI NG . Store at controlled room temperature 20-25°C (68-77°F) [see USP]. Rx Only Prescribing Information rev. Jun 2023 Distributed by: AbbVie, Inc. North Chicago, IL 60064 CARAFATE and its design are trademarks of Aptalis Pharma Canada ULC, an AbbVie company. © 2023 AbbVie. All rights reserved. v2.1USPI0170"],"geriatric_use":["Geriatric Use Clinical studies of CARAFATE Oral Suspension did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (See DOSAGE AND ADMINISTRATION ). This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function (See PRECAUTIONS Special Populations: Chronic Renal Failure and Dialysis Patients ). Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function."],"pediatric_use":["Pediatric U s e Safety and effectiveness in pediatric patients have not been established."],"effective_time":"20230608","nursing_mothers":["Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when sucralfate is administered to a nursing woman."],"clinical_studies":["CLINICAL TRIALS In a multicenter, double-blind, placebo-controlled study of CARAFATE Oral Suspension, a dosage regimen of 1 gram (10 mL) four times daily was demonstrated to be superior to placebo in ulcer healing. Resu l ts F r o m Clinical Trials Healing Rates f o r Acute Duo de nal Ulcer Treatment n Week 2 Healing Rates Week 4 Healing Rates Week 8 Healing Rates CARAFATE Oral Suspension 145 23(16%)* 66(46%) † 95(66%) ‡ Placebo 147 10(7%) 39(27%) 58(39%) * P =0.016 † P =0.001 ‡ P =0.0001 Equivalence of sucralfate oral suspension to sucralfate tablets has not been demonstrated."],"adverse_reactions":["ADV E RSE R EACTI O NS Adverse reactions to sucralfate tablets in clinical trials were minor and only rarely led to discontinuation of the drug. In studies involving over 2700 patients treated with sucralfate, adverse effects were reported in 129 (4.7%). Constipation was the most frequent complaint (2%). Other adverse effects reported in less than 0.5% of the patients are listed below by body system: Gastrointestinal: diarrhea, dry mouth, flatulence, gastric discomfort, indigestion, nausea, vomiting Derm a tolog i cal: pruritus, rash Ner v ous S y s tem: dizziness, insomnia, sleepiness, vertigo Oth e r: back pain, headache Post-marketing cases of hypersensitivity have been reported with the use of sucralfate oral suspension, including anaphylactic reactions, dyspnea, lip swelling, edema of the mouth, pharyngeal edema, pruritus, rash, swelling of the face and urticaria. Cases of bronchospasm, laryngeal edema and respiratory tract edema have been reported with an unknown oral formulation of sucralfate. Cases of hyperglycemia have been reported with sucralfate. Bezoars have been reported in patients treated with sucralfate. The majority of patients had underlying medical conditions that may predispose to bezoar formation (such as delayed gastric emptying) or were receiving concomitant enteral tube feedings."],"contraindications":["CONTRAINDICATIONS CARAFATE Oral Suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients."],"drug_interactions":["Drug Intera c tions Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. Subtherapeutic prothrombin times with concomitant warfarin and sucralfate therapy have been reported in spontaneous and published case reports. However, two clinical studies have demonstrated no change in either serum warfarin concentration or prothrombin time with the addition of sucralfate to chronic warfarin therapy. The mechanism of these interactions appears to be nonsystemic in nature, presumably resulting from sucralfate binding to the concomitant agent in the gastrointestinal tract. In all cases studied to date (cimetidine, ciprofloxacin, digoxin, norfloxacin, ofloxacin, and ranitidine), dosing the concomitant medication 2 hours before sucralfate eliminated the interaction. Due to CARAFATE Oral Suspension’s potential to alter the absorption of some drugs, CARAFATE Oral Suspension should be administered separately from other drugs when alterations in bioavailability are felt to be critical. In these cases, patients should be monitored appropriately."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine. Although the mechanism of sucralfate’s ability to accelerate healing of duodenal ulcers remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action. The following observations also appear pertinent: Studies in human subjects and with animal models of ulcer disease have shown that sucralfate forms an ulcer-adherent complex with proteinaceous exudate at the ulcer site. In vitro , a sucralfate-albumin film provides a barrier to diffusion of hydrogen ions. In human subjects, sucralfate given in doses recommended for ulcer therapy inhibits pepsin activity in gastric juice by 32%. In vitro , sucralfate adsorbs bile salts. These observations suggest that sucralfate’s antiulcer activity is the result of formation of an ulcer- adherent complex that covers the ulcer site and protects it against further attack by acid, pepsin, and bile salts. There are approximately 14 to 16 mEq of acid-neutralizing capacity per 1 g dose of sucralfate."],"indications_and_usage":["INDICATIONS AND USAGE CARAFATE (sucralfate) Oral Suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer."],"clinical_studies_table":["<table><col width=\"118\"/><col width=\"49\"/><col width=\"88\"/><col width=\"80\"/><col width=\"88\"/><tbody><tr><td styleCode=\"Toprule Lrule Rrule \" colspan=\"5\"><content styleCode=\"bold\">Resu</content><content styleCode=\"bold\">l</content><content styleCode=\"bold\">ts</content><content styleCode=\"bold\"> </content><content styleCode=\"bold\">F</content><content styleCode=\"bold\">r</content><content styleCode=\"bold\">o</content><content styleCode=\"bold\">m</content><content styleCode=\"bold\"> </content><content styleCode=\"bold\">Clinical</content><content styleCode=\"bold\"> </content><content styleCode=\"bold\">Trials</content><content styleCode=\"bold\"> </content><content styleCode=\"bold\">Healing</content><content styleCode=\"bold\"> </content><content styleCode=\"bold\">Rates</content><content styleCode=\"bold\"> </content><content styleCode=\"bold\">f</content><content styleCode=\"bold\">o</content><content styleCode=\"bold\">r</content><content styleCode=\"bold\"> </content><content styleCode=\"bold\">Acute</content><content styleCode=\"bold\"> </content><content styleCode=\"bold\">Duo</content><content styleCode=\"bold\">de</content><content styleCode=\"bold\">nal</content> <content styleCode=\"bold\">Ulcer</content></td></tr><tr><td styleCode=\"Toprule Lrule Rrule \">Treatment</td><td styleCode=\"Toprule Lrule Rrule \">n</td><td styleCode=\"Toprule Lrule Rrule \">Week 2 Healing Rates</td><td styleCode=\"Toprule Lrule Rrule \">Week 4 Healing Rates</td><td styleCode=\"Toprule Lrule Rrule \">Week 8 Healing Rates</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \">CARAFATE Oral Suspension</td><td styleCode=\"Toprule Lrule Rrule \">145</td><td styleCode=\"Toprule Lrule Rrule \">23(16%)*</td><td styleCode=\"Toprule Lrule Rrule \">66(46%)<sup>&#x2020;</sup></td><td styleCode=\"Toprule Lrule Rrule \">95(66%)<sup>&#x2021;</sup></td></tr><tr><td styleCode=\"Toprule Lrule Rrule \">Placebo</td><td styleCode=\"Toprule Lrule Rrule \">147</td><td styleCode=\"Toprule Lrule Rrule \">10(7%)</td><td styleCode=\"Toprule Lrule Rrule \">39(27%)</td><td styleCode=\"Toprule Lrule Rrule \">58(39%)</td></tr></tbody></table>"],"dosage_and_administration":["DOS A GE AN D A DMINIS T RAT I ON Acti v e Duodenal Ulcer : The recommended adult oral dosage for duodenal ulcer is 1 gram (10 mL) four times per day. CARAFATE Oral Suspension should be administered on an empty stomach. Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after CARAFATE Oral Suspension. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. Elderly : In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (See PRECAUTIONS , Geriatric Use ). Call your doctor for medical advice about side effects. You may report side effects to AbbVie, Inc at 1-800-678-1605 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"spl_product_data_elements":["Carafate Sucralfate SUCRALFATE SUCRALFATE SILICON DIOXIDE FD&C RED NO. 40 GLYCERIN METHYLCELLULOSE, UNSPECIFIED METHYLPARABEN MICROCRYSTALLINE CELLULOSE WATER SORBITOL SOLUTION Maraschino Cherry Artificial Flavor #2359"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL NDC 58914-170-14 Carafate ® (sucralfate) Oral Suspension 1 g/ 10 mL One 420 mL Bottle Rx ONLY PRINCIPAL DISPLAY PANEL NDC 58914-170-14 Carafate® (sucralfate) Oral Suspension 1g/ 10mL One 420 mL Bottle Rx ONLY"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carci n oge ne sis, Mutag en esis, Impairment of F e rt i li t y Chronic oral toxicity studies of 24 months’ duration were conducted in mice and rats at doses up to 1 g/kg (12 times the human dose). There was no evidence of drug-related tumorigenicity. A reproduction study in rats at doses up to 38 times the human dose did not reveal any indication of fertility impairment. Mutagenicity studies were not conducted."]},"tags":[{"label":"Aluminum Complex","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Pepsin A-5","category":"target"},{"label":"PGA5","category":"gene"},{"label":"A02BX02","category":"atc"},{"label":"Topical","category":"route"},{"label":"Oral","category":"route"},{"label":"Cream","category":"form"},{"label":"Suspension","category":"form"},{"label":"Tablet","category":"form"},{"label":"Active","category":"status"},{"label":"Duodenal ulcer disease","category":"indication"},{"label":"Maintenance of Healing Duodenal Ulcer","category":"indication"},{"label":"Forest Labs Inc","category":"company"},{"label":"Approved 1980s","category":"decade"},{"label":"Anti-Ulcer Agents","category":"pharmacology"},{"label":"Gastrointestinal Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":139.245,"date":"","count":55,"signal":"Vaginal flatulence","source":"DrugCentral FAERS","actionTaken":"Reported 55 times (LLR=139)"},{"llr":112.179,"date":"","count":60,"signal":"Female genital tract fistula","source":"DrugCentral FAERS","actionTaken":"Reported 60 times (LLR=112)"},{"llr":109.256,"date":"","count":61,"signal":"Proctitis","source":"DrugCentral FAERS","actionTaken":"Reported 61 times (LLR=109)"},{"llr":96.349,"date":"","count":58,"signal":"Vaginal discharge","source":"DrugCentral FAERS","actionTaken":"Reported 58 times (LLR=96)"},{"llr":95.862,"date":"","count":392,"signal":"Drug ineffective","source":"DrugCentral FAERS","actionTaken":"Reported 392 times (LLR=96)"},{"llr":95.537,"date":"","count":24,"signal":"Angina bullosa haemorrhagica","source":"DrugCentral FAERS","actionTaken":"Reported 24 times (LLR=96)"},{"llr":93.116,"date":"","count":9,"signal":"Contraindicated product administered","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=93)"},{"llr":91.705,"date":"","count":61,"signal":"Radiculopathy","source":"DrugCentral FAERS","actionTaken":"Reported 61 times (LLR=92)"},{"llr":86.186,"date":"","count":7,"signal":"Maternal exposure during pregnancy","source":"DrugCentral FAERS","actionTaken":"Reported 7 times (LLR=86)"},{"llr":84.236,"date":"","count":433,"signal":"Abdominal pain","source":"DrugCentral FAERS","actionTaken":"Reported 433 times (LLR=84)"},{"llr":77.759,"date":"","count":91,"signal":"Frequent bowel movements","source":"DrugCentral FAERS","actionTaken":"Reported 91 times (LLR=78)"},{"llr":77.253,"date":"","count":881,"signal":"Nausea","source":"DrugCentral FAERS","actionTaken":"Reported 881 times (LLR=77)"},{"llr":76.061,"date":"","count":80,"signal":"Oesophagitis","source":"DrugCentral FAERS","actionTaken":"Reported 80 times (LLR=76)"},{"llr":74.579,"date":"","count":65,"signal":"Toxicity to various agents","source":"DrugCentral FAERS","actionTaken":"Reported 65 times (LLR=75)"},{"llr":73.328,"date":"","count":30,"signal":"Early satiety","source":"DrugCentral FAERS","actionTaken":"Reported 30 times (LLR=73)"}],"drugInteractions":[{"url":"/drug/dolutegravir","drug":"dolutegravir","action":"Monitor closely","effect":"May interact with Dolutegravir, Sucralfate","source":"DrugCentral","drugSlug":"dolutegravir"},{"url":"/drug/gemifloxacin","drug":"gemifloxacin","action":"Monitor closely","effect":"May interact with Gemifloxacin, Sucralfate","source":"DrugCentral","drugSlug":"gemifloxacin"},{"url":"/drug/moxifloxacin","drug":"moxifloxacin","action":"Monitor closely","effect":"May interact with Moxifloxacin, Sucralfate","source":"DrugCentral","drugSlug":"moxifloxacin"},{"url":"/drug/zalcitabine","drug":"zalcitabine","action":"Monitor closely","effect":"SUCRALFATE/ZALCITABINE (DIDEOXYCYTIDINE,ddC)","source":"DrugCentral","drugSlug":"zalcitabine"}],"commonSideEffects":[{"effect":"Constipation","drugRate":"2%","_validated":true,"placeboRate":""}],"contraindications":["CARAFATE Oral Suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients."],"specialPopulations":{"Pregnancy":"Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.","Geriatric use":"In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function.","Paediatric use":"Safety and effectiveness in pediatric patients have not been established.","Renal impairment":"Sucralfate should be used with caution in patients with chronic renal failure. Aluminum accumulation and toxicity (aluminum osteodystrophy, osteomalacia, encephalopathy) have been described in patients with renal impairment."}},"trials":[],"aliases":[],"company":"Forest Labs Inc","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$4.5172/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$1,649","description":"CARAFATE 1 GM TABLET","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Carafate","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:25:41.003557+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:25:46.458985+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Carafate","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:25:46.811431+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:25:39.500481+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:25:39.500502+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:25:39.500507+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glycoproteins cross-linking agent","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:25:47.860346+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6067980/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:25:47.506718+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"ADV E RSE R EACTI O NS Adverse reactions to sucralfate tablets in clinical trials were minor and only rarely led to discontinuation of the drug. In studies involving over 2700 patients treated with sucralfate, adverse effects were reported in 129 (4.7%). Constipation was the most frequent complaint (2%). Other adverse effects reported in less than 0.5% of the patients are listed below by body system: Gastrointestinal: diarrhea, dry mouth, flatulence, gastric discomfort, indigestion, nausea, vomi","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:25:53.147209+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:25:57.476670+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA019183","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:25:39.500510+00:00"}},"allNames":["sucralfate","antepsin","carafate","sucralfin","sucrate","sulcrate","ulcerlmin","ulcogant"],"offLabel":[],"synonyms":["sucralfate","antepsin","carafate","sucralfin","sucrate","sulcrate","ulcerlmin","ulcogant"],"timeline":[{"date":"1981-10-30","type":"positive","source":"DrugCentral","milestone":"FDA approval (Forest Labs Inc)"}],"brandName":"Carafate","ecosystem":[{"indication":"Duodenal ulcer disease","otherDrugs":[{"name":"algeldrate","slug":"algeldrate","company":"Sanofi Aventis Us"},{"name":"cimetidine","slug":"cimetidine","company":""},{"name":"famotidine","slug":"famotidine","company":"Valeant Pharms North"},{"name":"lansoprazole","slug":"lansoprazole","company":"Takeda Pharms Usa"}],"globalPrevalence":null},{"indication":"Maintenance of Healing Duodenal Ulcer","otherDrugs":[{"name":"cimetidine","slug":"cimetidine","company":""},{"name":"famotidine","slug":"famotidine","company":"Valeant Pharms North"},{"name":"lansoprazole","slug":"lansoprazole","company":"Takeda Pharms Usa"},{"name":"nizatidine","slug":"nizatidine","company":""}],"globalPrevalence":null}],"mechanism":{"target":"Pepsin A-5","novelty":"First-in-class","targets":[{"gene":"PGA5","source":"DrugCentral","target":"Pepsin A-5","protein":"Pepsin A-5"}],"modality":"Small Molecule","drugClass":"Aluminum Complex [EPC]","explanation":"","oneSentence":"","technicalDetail":"Carafate, an aluminum complex, works by forming a gel-like barrier over the ulcer site, neutralizing gastric acid and binding to pepsin, thereby preventing further damage to the mucosal lining."},"commercial":{"launchDate":"1981","_launchSource":"DrugCentral (FDA 1981-10-30, FOREST LABS INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4106","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Carafate","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Carafate","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T02:42:34.949611","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:25:58.401817+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"bismuth subcitrate","drugSlug":"bismuth-subcitrate","fdaApproval":"2006-09-28","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"carafate","indications":{"approved":[{"name":"Duodenal ulcer disease","source":"DrugCentral","snomedId":51868009,"regulator":"FDA"},{"name":"Maintenance of Healing Duodenal Ulcer","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults with healed duodenal ulcers, at reduced dosage"}],"offLabel":[{"name":"Gastric ulcer","source":"DrugCentral","drugName":"Carafate"},{"name":"Gastroesophageal reflux disease","source":"DrugCentral","drugName":"Carafate","evidenceCount":96,"evidenceLevel":"strong"},{"name":"Gingivostomatitis","source":"DrugCentral","drugName":"Carafate","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Maintenance of Healing Gastric Ulcer","source":"DrugCentral","drugName":"Carafate","evidenceCount":36,"evidenceLevel":"moderate"},{"name":"NSAID-Induced Duodenal Ulcer","source":"DrugCentral","drugName":"Carafate","evidenceCount":25,"evidenceLevel":"moderate"},{"name":"Peptic reflux disease","source":"DrugCentral","drugName":"Carafate","evidenceCount":105,"evidenceLevel":"strong"},{"name":"Prevention of Stress Ulcer","source":"DrugCentral","drugName":"Carafate","evidenceCount":207,"evidenceLevel":"strong"},{"name":"Sclerotherapy Induced Esophageal Ulcer","source":"DrugCentral","drugName":"Carafate","evidenceCount":4,"evidenceLevel":"emerging"},{"name":"Sclerotherapy-Induced Mucositis","source":"DrugCentral","drugName":"Carafate","evidenceCount":1,"evidenceLevel":"emerging"},{"name":"Stomatitis","source":"DrugCentral","drugName":"Carafate","evidenceCount":79,"evidenceLevel":"strong"},{"name":"Stress-Related GI Mucosal Bleeding Prevention","source":"DrugCentral","drugName":"Carafate"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"bismuth-subcitrate","brandName":"bismuth subcitrate","genericName":"bismuth subcitrate","approvalYear":"2006","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07312370","phase":"PHASE4","title":"Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing","status":"NOT_YET_RECRUITING","sponsor":"LanZhou University","startDate":"2026-04-20","conditions":["Early Gastric Cancer","Gastric Dysplasia","Gastric Neoplasms","Peptic Ulcer With Haemorrhage","Gastric Ulcer"],"enrollment":120,"completionDate":"2026-12-30"},{"nctId":"NCT07310927","phase":"PHASE2,PHASE3","title":"Alginate vs Sucralfate for GERD Symptomatic Relief","status":"RECRUITING","sponsor":"CMH Lahore Medical College and Institute of Dentistry","startDate":"2025-04-01","conditions":["GERD"],"enrollment":140,"completionDate":"2026-04"},{"nctId":"NCT05659576","phase":"PHASE2","title":"Reducing Acute Upper Gastrointestinal Side-Effects of Thoracic Irradiation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-12-13","conditions":["Radiation Esophagitis"],"enrollment":142,"completionDate":"2026-12"},{"nctId":"NCT07257926","phase":"PHASE4","title":"Prevention of Delayed Post-polypectomy Bleeding by Endoscopic Sucralfate Spray in High-risk Patients: A Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"National Cheng-Kung University Hospital","startDate":"2025-12-15","conditions":["Bleeding After GI Endoscopy"],"enrollment":160,"completionDate":"2027-12-31"},{"nctId":"NCT06421389","phase":"NA","title":"Precise Endoscopic Application of Tranexamic Acid and Sucralfate in Gastrointestinal Bleeding: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2024-08-15","conditions":["Bleed Ulcer"],"enrollment":60,"completionDate":"2025-06-30"},{"nctId":"NCT06107504","phase":"NA","title":"Prevention of Post-sphincterotomy Bleeding","status":"RECRUITING","sponsor":"National Cheng-Kung University Hospital","startDate":"2024-01-01","conditions":["Post-ERCP Bleeding"],"enrollment":120,"completionDate":"2025-07-31"},{"nctId":"NCT04918758","phase":"NA","title":"Endoscopically-delivered Purastat to Treat Bleeding Caused by Radiation Proctopathy","status":"COMPLETED","sponsor":"Manchester University NHS Foundation Trust","startDate":"2021-07-22","conditions":["Radiation Proctopathy"],"enrollment":26,"completionDate":"2024-12-31"},{"nctId":"NCT06617026","phase":"PHASE1,PHASE2","title":"Short-Term Outcome of Medical Vs. Surgical Management Of Chronic Anal Fissure","status":"COMPLETED","sponsor":"Suez Canal University","startDate":"2024-08-30","conditions":["Anal Fissure Chronic"],"enrollment":99,"completionDate":"2024-10-01"},{"nctId":"NCT05369234","phase":"PHASE3","title":"Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis","status":"COMPLETED","sponsor":"Covenant Health Cancer Center","startDate":"2022-01-20","conditions":["Oral Cavity Cancer","Head and Neck Cancers - Tonsils","Esophageal Cancer","Laryngeal Cancer","Oropharynx Cancer","Mediastinal Cancer","Chest Wall Tumor","Radiation Mucositis"],"enrollment":100,"completionDate":"2024-01-30"},{"nctId":"NCT05817656","phase":"PHASE1","title":"Colonoscopic Sucralfate Spray in Prevention of Delayed Polypectomy Bleeding","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2023-05-15","conditions":["Bleeding"],"enrollment":160,"completionDate":"2024-04-14"},{"nctId":"NCT04171466","phase":"NA","title":"Metagenomic and Metabolomic Reconstitution of Gut Microbiota After Broad Spectrum Antibiotic Therapy","status":"COMPLETED","sponsor":"Seed Health","startDate":"2020-08-12","conditions":["Antibiotic Side Effect","Antibiotic-associated Diarrhea","Antibiotic-induced Dysbiosis","Antibiotic-induced Epithelial Barrier Disintegrity"],"enrollment":46,"completionDate":"2022-09-07"},{"nctId":"NCT02788591","phase":"NA","title":"Confocal Endomicroscopy for Non-Erosive Reflux Disease Detection","status":"TERMINATED","sponsor":"LCMC Health","startDate":"2015-08","conditions":["Non-erosive Reflux Disease","Gastroesophageal Reflux"],"enrollment":5,"completionDate":"2021-06"},{"nctId":"NCT03241030","phase":"PHASE2","title":"Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial","status":"COMPLETED","sponsor":"University of Texas at Austin","startDate":"2017-09-12","conditions":["Herpangina","Gingivostomatitis","Hand, Foot and Mouth Disease"],"enrollment":102,"completionDate":"2019-06-20"},{"nctId":"NCT03400254","phase":"PHASE1,PHASE2","title":"Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer (\"GLACIER\")","status":"WITHDRAWN","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2019-02-26","conditions":["Breast Cancer"],"enrollment":0,"completionDate":"2019-11-12"},{"nctId":"NCT04327869","phase":"","title":"MCE Direct Visualization of Drug Behavior in Upper-gastrointestinal Tract","status":"COMPLETED","sponsor":"Changhai Hospital","startDate":"2018-11-03","conditions":["Capsule Endoscopy"],"enrollment":20,"completionDate":"2020-02-14"},{"nctId":"NCT00584922","phase":"","title":"Early Detection and Treatment of Esophageal Injury After Catheter Ablation for Atrial Fibrillation","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2006-12-05","conditions":["Atrial Fibrillation"],"enrollment":175,"completionDate":"2011-12"},{"nctId":"NCT03635372","phase":"PHASE4","title":"A Comparison of Effectiveness of Oral Sucrolfate, Alginate and Hydrotalcide in Dispeptic Pain Treatment","status":"COMPLETED","sponsor":"Pamukkale University","startDate":"2017-06-20","conditions":["Dyspepsia"],"enrollment":300,"completionDate":"2017-11-25"},{"nctId":"NCT02353078","phase":"EARLY_PHASE1","title":"The Effect of Sucralfate Slurry in Patients With Eosinophilic Esophagitis","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2015-01","conditions":["Eosinophilic Esophagitis"],"enrollment":3,"completionDate":"2016-12"},{"nctId":"NCT02039869","phase":"NA","title":"Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)","status":"WITHDRAWN","sponsor":"Virginia Commonwealth University","startDate":"","conditions":["Gastroesophageal Reflux Disease","Non Erosive Reflux Disease","Dyspepsia"],"enrollment":0,"completionDate":""},{"nctId":"NCT02037399","phase":"NA","title":"Pilot Trial on Efficacy of Single Dose Perioperative Intravenous Dexamethasone for Pain Relief After Endoscopic Submucosal Dissection","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2013-07","conditions":["Early Gastric Cancer or Gastric Adenoma"],"enrollment":50,"completionDate":"2014-02"},{"nctId":"NCT01284647","phase":"PHASE4","title":"A Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis","status":"COMPLETED","sponsor":"Changhai Hospital","startDate":"2011-02","conditions":["Chronic Erosive Gastritis"],"enrollment":156,"completionDate":"2013-06"},{"nctId":"NCT02016807","phase":"","title":"ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial","status":"UNKNOWN","sponsor":"Ashley Downs Bioscience","startDate":"2013-01","conditions":["Oral Mucositis","Nausea","Vomiting","Diarrhea"],"enrollment":180,"completionDate":"2015-01"},{"nctId":"NCT01613534","phase":"PHASE4","title":"Combined Therapy in Radiation Proctopathy","status":"COMPLETED","sponsor":"Maria Sklodowska-Curie National Research Institute of Oncology","startDate":"2003-06","conditions":["Chronic Radiation Proctitis"],"enrollment":122,"completionDate":"2007-06"},{"nctId":"NCT00814359","phase":"PHASE3","title":"Magic Mouthwash Plus Sucralfate Versus Benzydamine Hydrochloride for the Treatment of Radiation-induced Mucositis","status":"COMPLETED","sponsor":"Juravinski Cancer Centre Foundation","startDate":"2009-05","conditions":["Head and Neck Cancer","Mucositis"],"enrollment":67,"completionDate":"2010-09"},{"nctId":"NCT00702871","phase":"PHASE4","title":"A Clinico-Bacteriological Study and Effect of Stress Ulcer Prophylaxis on Occurrence of Ventilator Associated Pneumonia","status":"COMPLETED","sponsor":"Maulana Azad Medical College","startDate":"2005-03","conditions":["Ventilator Associated Pneumonia","Etiological Organisms","Antimicrobial Drug Susceptibility Pattern","Stress Ulcer Prophylaxis"],"enrollment":50,"completionDate":"2006-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Cream, Suspension, Tablet","formulations":[{"form":"CREAM","route":"TOPICAL","productName":"Varecell Intensive Liposome DoubleCream"},{"form":"SUSPENSION","route":"ORAL","productName":"Sucralfate"},{"form":"SUSPENSION","route":"ORAL","productName":"sucralfate"},{"form":"SUSPENSION","route":"ORAL","productName":"Carafate"},{"form":"SUSPENSION","route":"ORAL","productName":"SUCRALFATE"},{"form":"SUSPENSION","route":"ORAL","productName":"Sucralfate"},{"form":"SUSPENSION","route":"ORAL","productName":"Sucralfate"},{"form":"SUSPENSION","route":"ORAL","productName":"Sucralfate"},{"form":"TABLET","route":"ORAL","productName":"SUCRALFATE"},{"form":"TABLET","route":"ORAL","productName":"Sucralfate"},{"form":"TABLET","route":"ORAL","productName":"Carafate"},{"form":"TABLET","route":"ORAL","productName":"Sucralfate"},{"form":"TABLET","route":"ORAL","productName":"Sucralfate"},{"form":"TABLET","route":"ORAL","productName":"Sucralfate"}]},"crossReferences":{"NUI":"N0000147119","MMSL":"1948","NDDF":"001132","UNII":"XX73205DH5","VUID":"4018816","CHEBI":"CHEBI:9313","VANDF":"4018816","INN_ID":"2723","RXNORM":"10156","UMLSCUI":"C0038633","chemblId":"CHEMBL6067980","ChEMBL_ID":"CHEMBL3989780","DRUGBANK_ID":"DB00364","PUBCHEM_CID":"121494085","SNOMEDCT_US":"387387008","IUPHAR_LIGAND_ID":"7055","MESH_DESCRIPTOR_UI":"D013392"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1981-","companyName":"Forest Labs Inc","relationship":"Original Developer"}],"publicationCount":19,"therapeuticAreas":["Pain"],"atcClassification":{"source":"DrugCentral","atcCode":"A02BX02","allCodes":["A02BX02"]},"biosimilarFilings":[],"originalDeveloper":"Forest Labs Inc","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Forest Labs Inc","companyId":"forest-labs-inc","modality":"Small molecule","firstApprovalDate":"1981","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:25:58.401817+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}